Literature DB >> 12226802

Pseudomonas aeruginosa: resistance and therapy.

Burke A Cunha1.   

Abstract

Pseudomonas aeruginosa resistance to antimicrobials is an important therapeutic consideration. Antibiotic resistance to P. aeruginosa may be chromosomally or plasmid mediated. Resistance to P. aeruginosa may also be affected by changes in the cellular membrane or intracellular environment. P. aeruginosa is primarily a nosocomial organism that most commonly colonizes respiratory secretions and urine. The selection of an antipseudomonal antibiotic depends on its inherent in vitro activity and its resistance potential. Anti-P. aeruginosa antibiotics with a high-resistance potential include gentamicin, tobramycin, ciprofloxacin, ceftazidime, and imipenem. Anti-P. aeruginosa antibiotics with a low-resistance potential include amikacin, piperacillin, cefoperazone, cefepime, meropenem, and polymyxin B. Copyright 2002, Elsevier Science (USA). All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12226802     DOI: 10.1053/srin.2002.34689

Source DB:  PubMed          Journal:  Semin Respir Infect        ISSN: 0882-0546


  8 in total

1.  Green nail syndrome treated with the application of tobramycin eye drop.

Authors:  Youin Bae; Gang Mo Lee; Ji Hoon Sim; Sanghoon Lee; Sung Yul Lee; Young Lip Park
Journal:  Ann Dermatol       Date:  2014-07-31       Impact factor: 1.444

2.  [Pseudomonas aeruginosa infection presenting as gonorrhea].

Authors:  I Schugt; P Altmeyer; N H Brockmeyer
Journal:  Hautarzt       Date:  2004-11       Impact factor: 0.751

3.  Mortality of COPD patients infected with multi-resistant Pseudomonas aeruginosa: a case and control study.

Authors:  M Montero; M Domínguez; M Orozco-Levi; M Salvadó; H Knobel
Journal:  Infection       Date:  2008-12-05       Impact factor: 3.553

4.  Development of resistance in wild-type and hypermutable Pseudomonas aeruginosa strains exposed to clinical pharmacokinetic profiles of meropenem and ceftazidime simulated in vitro.

Authors:  Beate Henrichfreise; Irith Wiegand; Ingeborg Luhmer-Becker; Bernd Wiedemann
Journal:  Antimicrob Agents Chemother       Date:  2007-08-06       Impact factor: 5.191

Review 5.  Current treatment of pseudomonal infections in the elderly.

Authors:  Georgios Pappas; Kaiti Saplaoura; Matthew E Falagas
Journal:  Drugs Aging       Date:  2009       Impact factor: 3.923

6.  Assessment of the Appropriateness of Ceftazidime Use in a Tertiary Teaching Hospital, Northern Ethiopia.

Authors:  Teklu Gebrehiwot Gebremichael; Hiluf Hindeya Gebreyesus; Alem Gebremariam
Journal:  Drug Healthc Patient Saf       Date:  2019-12-20

7.  Identification of small molecule inhibitors of Pseudomonas aeruginosa exoenzyme S using a yeast phenotypic screen.

Authors:  Anthony Arnoldo; Jasna Curak; Saranya Kittanakom; Igor Chevelev; Vincent T Lee; Mehdi Sahebol-Amri; Becky Koscik; Lana Ljuma; Peter J Roy; Antonio Bedalov; Guri Giaever; Corey Nislow; A Rod Merrill; Rod A Merrill; Stephen Lory; Igor Stagljar
Journal:  PLoS Genet       Date:  2008-02-29       Impact factor: 5.917

8.  Chemical Compositions and Antimicrobial Activities of Ocimum sanctum L. Essential Oils at Different Harvest Stages.

Authors:  Mohammad Jamal Saharkhiz; Amir Alam Kamyab; Narges Khatoon Kazerani; Kamiar Zomorodian; Keyvan Pakshir; Mohammad Javad Rahimi
Journal:  Jundishapur J Microbiol       Date:  2014-12-06       Impact factor: 0.747

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.